Traded Apr 15 · filed the same day
Compensation award — excluded from discretionary-purchase analysis.
Loading…
Traded Mar 17, 2026 · Filed Mar 18, 2026
The CEO of Cytokinetics sold $788K of Cytokinetics shares. The filing references tax withholding.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$787,627
Shares × reported transaction price
21 days after results of Feb 24, 2026, 49 days before results of May 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references tax withholding
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +0.8% | −2.2% | +3.1% |
| 30 days | +5.1% | +7.4% | −2.3% |
| 90 days | +24.1% | +12.3% | +11.8% |
| 180 days | +10.1% | +14.8% | −4.7% |
Past results only. Not a forecast.
Traded Apr 15 · filed the same day
Compensation award — excluded from discretionary-purchase analysis.
Traded Apr 15 · filed the same day
Compensation award — excluded from discretionary-purchase analysis.
Traded Apr 15 · filed the same day
Compensation award — excluded from discretionary-purchase analysis.